An Open Label, Phase I Study to Assess the Effect of Itraconazole (CYP3A4 and P-gp Inhibitor) on the Pharmacokinetics of Anetumab Ravtansine and to Assess the ECG Effects, Safety and Immunogenicity of Anetumab Ravtansine Given as a Single Agent and Together With Itraconazole in Subjects With Mesothelin-expressing Advanced Solid Cancers

Trial Profile

An Open Label, Phase I Study to Assess the Effect of Itraconazole (CYP3A4 and P-gp Inhibitor) on the Pharmacokinetics of Anetumab Ravtansine and to Assess the ECG Effects, Safety and Immunogenicity of Anetumab Ravtansine Given as a Single Agent and Together With Itraconazole in Subjects With Mesothelin-expressing Advanced Solid Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2017

At a glance

  • Drugs Anetumab ravtansine (Primary) ; Itraconazole
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 18 Sep 2017 Planned number of patients changed from 48 to 61.
    • 18 Sep 2017 Planned primary completion date changed from 25 May 2018 to 31 Oct 2018.
    • 31 Jul 2017 Planned primary completion date changed from 22 Mar 2018 to 25 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top